NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States Remove constraint Subjects: United States Languages English Remove constraint Languages: English

Search Results

6204. Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval

6205. Enforcement policy for viral transport media during the Coronavirus disease 2019 (COVID-19) public health emergency: guidance for commercial manufacturers, clinical laboratories, and Food and Drug Administration staff

6206. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff

6207. Cancer clinical trial eligibility criteria: minimum age considerations for inclusion of pediatric patients : guidance for industry and IRBs

6209. Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies

6210. Marketing status notifications under Section 506I of the Federal Food, Drug, and Cosmetic Act: content and format